A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)
NCT05420909 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 124
Last updated 2022-08-19
Summary
The purpose of this study is to estimate the overall survival (OS) for US participants diagnosed with metastatic colorectal cancer (mCRC) by using Flatiron Health's individual patient level data.
Conditions
- Metastatic Colorectal Cancer (mCRC)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-01-28
- Primary Completion
- 2019-03-01
- Completion
- 2019-04-01
Countries
- United States
Study Locations
More Related Trials
-
An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States
NCT06029010 ·Status: COMPLETED
-
CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer
NCT00932724 ·Status: TERMINATED ·Phase: PHASE2
-
Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment
NCT00717990 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
NCT05725200 ·Status: RECRUITING ·Phase: PHASE2
-
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
NCT03592641 ·Status: TERMINATED ·Phase: PHASE2
-
Gemcitabine-UFTE Chemotherapy in Refractory Colorectal Cancer
NCT01409005 ·Status: COMPLETED ·Phase: PHASE2
-
AGMT Metastatic Colorectal Cancer Registry (mCRC) Third Line and Beyond
NCT06678919 ·Status: RECRUITING
-
Efficacy and Safety of Regorafenib Maintenance Therapy in Patients With Metastatic Colorectal Cancer (mCRC)
NCT05818267 ·Status: RECRUITING ·Phase: NA
-
Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
NCT00138060 ·Status: COMPLETED ·Phase: PHASE4
-
Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)
NCT02612077 ·Status: COMPLETED
-
Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies
NCT01607957 ·Status: COMPLETED ·Phase: PHASE3
-
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT01075048 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
NCT07134205 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
NCT04457284 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment
NCT02618850 ·Status: UNKNOWN ·Phase: NA
-
Nivolumab+Ipilimumab+RT in MSS mCRC
NCT04575922 ·Status: UNKNOWN ·Phase: PHASE2
-
Ro 31-7453 in Treating Patients With Recurrent or Refractory Metastatic Colorectal Cancer
NCT00016250 ·Status: COMPLETED ·Phase: PHASE2
-
Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer
NCT02286492 ·Status: APPROVED_FOR_MARKETING
-
Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer
NCT06341309 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF
NCT01367275 ·Status: TERMINATED ·Phase: PHASE2
-
Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)
NCT03909724 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Escalated Dose of Irinotecan in mCRC
NCT02256800 ·Status: COMPLETED ·Phase: NA
-
An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer
NCT01319877 ·Status: COMPLETED
-
Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment
NCT01983098 ·Status: UNKNOWN
-
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
NCT05328908 ·Status: TERMINATED ·Phase: PHASE3